123748 ((EXCLUSIVE))

N1 - Funding Information:This work was supported by the National Institute of Mental Health (Grant Nos. MH101874 [to SJM and CFZ], MH114866 [to CFZ], MH123748 [to SJM ], MH122379 [to CFZ and SJM ]); the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of General Medical Sciences (Grant Nos. P30DK020579, P30DK056341, and P41GM103422 [to F-FH]); the Taylor Family Institute for Innovative Psychiatric Research ; and the Bantly Foundation . Funding Information:This work was supported by the National Institute of Mental Health (Grant Nos. MH101874 [to SJM and CFZ], MH114866 [to CFZ], MH123748 [to SJM], MH122379 [to CFZ and SJM]); the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of General Medical Sciences (Grant Nos. P30DK020579, P30DK056341, and P41GM103422 [to F-FH]); the Taylor Family Institute for Innovative Psychiatric Research; and the Bantly Foundation. We thank Kazuko Izumi and Ann Benz for technical assistance and members of the Taylor Family Institute for helpful comments and advice. YI, SJM, CRC, PN, and CFZ conceived the experiments; YI and CFZ designed the research and analyzed the data; YI performed the experiments; F-FH did measurements of N2O and CO2; CFZ wrote the article, and all authors edited and revised the article. CFZ serves on the Scientific Advisory Board of Sage Therapeutics and has equity in Sage Therapeutics. Sage Therapeutics did not fund this research. CRC is a consultant to Sage Therapeutics and has research sponsored by Sage Therapeutics. PN has filed for intellectual property protection for the use of nitrous oxide in TRMD and is founder of NitroBiomedical, LLC. All other authors report no biomedical financial interests or potential conflicts of interest.Publisher Copyright: 2022 Society of Biological Psychiatry

123748

041b061a72